Company intelligence / Profile preview

Cananji Pharmaceutical Technology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Cananji Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and autoimmune diseases through the development of highly selective inhibitors. Its lead programs include HPK1 inhibitors for immuno-oncology and next-generation EGFR inhibitors designed to overcome resistance in lung cancer. Cananji leverages its internal R&D capabilities to advance a pipeline of candidates from discovery through clinical proof-of-concept.

Therapeutic areas: ImmunologyDermatologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Cananji Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cananji Pharmaceutical Technology.

Explore the full profile